In
HIV and ID Observations, Dr. Paul Sax discusses the results of the SCORPIO-HR study.
We might be fooled into thinking that we no longer need better treatments for COVID-19, says Dr. Paul Sax, but this would be a mistake. But how will we get better treatments? This is one of the questions raised by SCORPIO-HR, a study of ensitrelvir for the treatment of nonhospitalized adults with COVID-19. Read more in the latest HIV and ID Observations.
Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Follow Via Email box.
Want to see more from NEJM Journal Watch? Register here.